XTX Topco Ltd Invests $1.39 Million in Intra-Cellular Therapies, Inc. (NASDAQ:ITCI)

XTX Topco Ltd bought a new stake in Intra-Cellular Therapies, Inc. (NASDAQ:ITCI) in the 2nd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The institutional investor bought 20,220 shares of the biopharmaceutical company’s stock, valued at approximately $1,385,000.

A number of other hedge funds have also recently modified their holdings of the stock. Seven Eight Capital LP purchased a new position in Intra-Cellular Therapies during the 2nd quarter worth approximately $1,501,000. Vanguard Personalized Indexing Management LLC grew its position in shares of Intra-Cellular Therapies by 20.0% during the second quarter. Vanguard Personalized Indexing Management LLC now owns 6,312 shares of the biopharmaceutical company’s stock worth $432,000 after acquiring an additional 1,052 shares during the last quarter. Amalgamated Bank increased its holdings in shares of Intra-Cellular Therapies by 117.3% in the 2nd quarter. Amalgamated Bank now owns 6,922 shares of the biopharmaceutical company’s stock valued at $474,000 after acquiring an additional 3,736 shares during the period. Virtu Financial LLC acquired a new position in shares of Intra-Cellular Therapies in the 2nd quarter valued at $1,420,000. Finally, Renaissance Technologies LLC raised its position in Intra-Cellular Therapies by 130.0% in the 2nd quarter. Renaissance Technologies LLC now owns 222,400 shares of the biopharmaceutical company’s stock valued at $15,232,000 after purchasing an additional 125,700 shares during the last quarter. 92.33% of the stock is owned by hedge funds and other institutional investors.

Analysts Set New Price Targets

A number of research analysts have commented on the stock. JPMorgan Chase & Co. lifted their price objective on shares of Intra-Cellular Therapies from $79.00 to $81.00 and gave the company an “overweight” rating in a research note on Wednesday, August 21st. UBS Group dropped their price target on Intra-Cellular Therapies from $83.00 to $79.00 and set a “neutral” rating on the stock in a research report on Thursday, August 8th. Piper Sandler upgraded Intra-Cellular Therapies from a “neutral” rating to an “overweight” rating and lifted their target price for the company from $68.00 to $92.00 in a research note on Friday, September 6th. Canaccord Genuity Group boosted their target price on Intra-Cellular Therapies from $107.00 to $113.00 and gave the company a “buy” rating in a report on Thursday, June 20th. Finally, Needham & Company LLC reaffirmed a “buy” rating and set a $100.00 price target on shares of Intra-Cellular Therapies in a report on Wednesday, August 7th. Three equities research analysts have rated the stock with a hold rating and ten have given a buy rating to the stock. According to MarketBeat, the company presently has a consensus rating of “Moderate Buy” and a consensus price target of $96.58.

Insider Buying and Selling at Intra-Cellular Therapies

In other news, CEO Sharon Mates sold 34,396 shares of Intra-Cellular Therapies stock in a transaction on Friday, August 30th. The stock was sold at an average price of $72.84, for a total transaction of $2,505,404.64. Following the completion of the transaction, the chief executive officer now owns 1,070,329 shares of the company’s stock, valued at approximately $77,962,764.36. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. In other news, CEO Sharon Mates sold 34,396 shares of the firm’s stock in a transaction that occurred on Friday, August 30th. The shares were sold at an average price of $72.84, for a total transaction of $2,505,404.64. Following the completion of the transaction, the chief executive officer now directly owns 1,070,329 shares of the company’s stock, valued at approximately $77,962,764.36. The sale was disclosed in a filing with the SEC, which is available at the SEC website. Also, Director Rory B. Riggs sold 4,462 shares of the company’s stock in a transaction that occurred on Monday, June 24th. The shares were sold at an average price of $75.57, for a total value of $337,193.34. Following the completion of the sale, the director now directly owns 116,600 shares in the company, valued at approximately $8,811,462. The disclosure for this sale can be found here. Over the last 90 days, insiders have sold 179,778 shares of company stock valued at $13,374,538. Insiders own 3.40% of the company’s stock.

Intra-Cellular Therapies Trading Up 0.8 %

Shares of ITCI opened at $77.61 on Friday. Intra-Cellular Therapies, Inc. has a twelve month low of $45.50 and a twelve month high of $84.89. The firm has a market capitalization of $8.19 billion, a P/E ratio of -66.91 and a beta of 1.00. The firm’s 50-day moving average is $75.67 and its two-hundred day moving average is $71.44.

Intra-Cellular Therapies (NASDAQ:ITCI) last released its quarterly earnings results on Wednesday, August 7th. The biopharmaceutical company reported ($0.16) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.19) by $0.03. The business had revenue of $161.40 million for the quarter, compared to analysts’ expectations of $157.74 million. Intra-Cellular Therapies had a negative return on equity of 11.48% and a negative net margin of 14.93%. The company’s revenue was up 45.7% compared to the same quarter last year. During the same quarter in the prior year, the firm posted ($0.45) EPS. Analysts predict that Intra-Cellular Therapies, Inc. will post -0.59 EPS for the current year.

Intra-Cellular Therapies Profile

Intra-Cellular Therapies, Inc, a biopharmaceutical company, focuses on the discovery, clinical development, and commercialization of small molecule drugs that address medical needs primarily in neuropsychiatric and neurological disorders by targeting intracellular signaling mechanisms in the central nervous system (CNS) in the United States.